Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

53 54 Next >

Axmed raises $2 million to transform access to critical medicines in low and middle income countries

May 08, 2024

Axmed’s B2B marketplace aggregates demand for critical medicines in underserved regions to improve the availability, affordability, and distribution of life-saving medicine.

Via News Direct

Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions

May 08, 2024

Via AB Newswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 07, 2024

From Arvinas Inc.

Via GlobeNewswire

Is NYSE:NVS a Good Fit for Dividend Investing? ↗

May 07, 2024

Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?

Via Chartmill

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise ↗

April 23, 2024

Shares have risen markedly over the past two days and gained again Tuesday.

Via Investor's Business Daily

Looking At Novartis's Recent Unusual Options Activity ↗

April 11, 2024

Via Benzinga

2 Magnificent Dividend Stocks to Hold for the Next Decade ↗

May 05, 2024

The dividend is just one reason to buy these stocks.

Via The Motley Fool

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗

May 01, 2024

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...

Via Benzinga

Topics Intellectual Property

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib ↗

April 29, 2024

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...

Via Benzinga

AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales ↗

April 29, 2024

The company is projected to bring in increasing sales through at least 2029.

Via Investor's Business Daily

Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗

April 28, 2024

The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...

Via Talk Markets

What's Going On With Pfizer Stock On Thursday? ↗

April 25, 2024

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.

Via Benzinga

Topics Intellectual Property

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

Why Novartis Stock Topped the Market on Tuesday ↗

April 23, 2024

A double beat on the latest quarterly results and raised guidance made investors happy.

Via The Motley Fool

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors ↗

April 23, 2024

Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by...

Via Benzinga

NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024 ↗

April 23, 2024

NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday? ↗

April 23, 2024

Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. Spotify shares jump 17% on earnings.

Via Benzinga

Topics Economy Stocks

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript ↗

April 23, 2024

NVS earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook ↗

April 23, 2024

Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.

Via Benzinga

Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback' ↗

April 23, 2024

The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose...

Via Benzinga

Topics Bonds

Top Analyst Reports For Novartis, American Express & ConocoPhillips ↗

April 22, 2024

Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).

Via Talk Markets

The Bad News Heading Into AbbVie's First-Quarter Earnings Report ↗

April 19, 2024

AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."

Via Investor's Business Daily

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗

April 19, 2024

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

Via Benzinga

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗

April 17, 2024

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.

Via Benzinga

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years ↗

April 17, 2024

These income stocks look like good options at current levels.

Via The Motley Fool

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades ↗

April 16, 2024

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

Via Benzinga

Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. ↗

April 14, 2024

Think globally with this high-yielding ETF.

Via The Motley Fool

Topics ETFs

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗

April 11, 2024

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today